Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
HealthDay News — An initial phase of multifood sublingual immunotherapy (SLIT) that bypasses oral immunotherapy (OIT) buildup is safe and effective, according to a study published online February 27 in the Journal of Allergy and Clinical Immunology: In Practice.
Lianne Soller, PhD, from the University of British Columbia in Vancouver, Canada, and colleagues assessed the safety of multifood SLIT in 188 pediatric patients (aged 4 to 18 years) and the effectiveness of bypassing oral immunotherapy (OIT) buildup with an initial phase of SLIT.
The researchers found that 4 patients received epinephrine (2.10%) during buildup (2mg protein SLIT maintenance over the course of 3 to 5 visits) and went to the emergency department, although none experienced grade 4 (severe) reaction. Twenty patients had 50 low-dose oral food challenges to 300mg protein, with 70% of the oral food challenges successful in bypassing OIT buildup.
“Allergists are often quite burdened by the oral immunotherapy buildup phase, where a patient may require 11 or more visits to the clinic,” coauthor Edmond Chan, MD, also from the University of British Columbia, said in a statement. “In our clinic, we are starting to do more home-based approaches because the demand for medical appointments that would allow supervision far outstrips the supply. Our SLIT data suggests that home-based SLIT buildup is safe.”
Several authors disclosed ties to the pharmaceutical industry.
